ST Germain D J Co. Inc. Purchases 16,640 Shares of Johnson & Johnson $JNJ

Key Points

• ST Germain D J Co. Inc. increased its holdings in Johnson & Johnson by 11% during the second quarter, owning a total of 167,774 shares worth approximately $25.6 million.
• Johnson & Johnson reported a quarterly EPS of $2.77, beating analyst expectations, and set its FY 2025 guidance at 10.800-10.900 EPS.
• The company declared a quarterly dividend of $1.30 per share, yielding 2.9%, with a payout ratio currently at 55.61%.

ST Germain D J Co. Inc. grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 167,774 shares of the company's stock after purchasing an additional 16,640 shares during the quarter. Johnson & Johnson makes up approximately 1.1% of ST Germain D J Co. Inc.'s portfolio, making the stock its 26th largest holding. ST Germain D J Co. Inc.'s holdings in Johnson & Johnson were worth $25,627,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of JNJ. Highline Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the first quarter worth $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 1.1%

Shares of NYSE:JNJ opened at $179.69 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company's fifty day moving average is $174.41 and its 200-day moving average is $162.06. The company has a market capitalization of $432.75 billion, a PE ratio of 19.22, a P/E/G ratio of 2.26 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 EPS. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Citigroup lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research note on Thursday, August 21st. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $167.00 to $206.00 in a research note on Tuesday. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Finally, Bank of America lifted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $181.40.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.